A series of cardiometabolic-related news items has been observed from Abbott, Kailera Therapeutics, MiniMed, and Insulet. Below, FENIX provides highlights and insights for the respective news items.
With ADA 2026 approaching (June 5-8; New Orleans, LA), FENIX has compiled a shortlist of key sessions and presentations that warrant close attention across the meeting. While ADA brings new data and fresh perspectives across the cardiometabolic space each year, the list below focuses exclusively on the sessions with potential to shape this year’s conference narrative and ultimately, have an outsized impact on the field for years to come.
A series of cardiometabolic-related news items has been observed from EMA, Lilly, Beta Bionics, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from FDA, Novo Nordisk, Altimmune, Lilly, and Insulet. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Arrowhead, Structure Therapeutics, Senseonics, Tandem Diabetes Care, and Pfizer. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: Madrigal Pharmaceuticals hosted its Q1 ’26 earnings call (view press release; view slides) and Insulet hosted its Q1 ’26 earnings call (view press release; view slides). Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Sirius Therapeutics posted a new Ph1/2 obesity study on CT.gov (view CT.gov record); Amgen expanded its investment in US manufacturing by an additional $300M (view press release); and Insulet initiated its EVOLVE FCL study in T2DM (view press release). Below, FENIX provides highlights and insights on the respective news items.
A series of cardiometabolic-related news items has been observed from Ascletis Pharma, GSK, Tandem Diabetes, and Sagimet Biosciences. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from CMS, Sanofi, Beta Bionics, and Pfizer. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk/Boehringer Ingelheim, MetaVia, LifeMD, Modular Medical, and FDA/MiniMed. Below, FENIX provides highlights and insights for the respective news items.